PMID- 15939720
OWN - NLM
STAT- MEDLINE
DCOM- 20060127
LR  - 20200203
IS  - 0923-7534 (Print)
IS  - 0923-7534 (Linking)
VI  - 16
IP  - 9
DP  - 2005 Sep
TI  - Clinical significance of cytogenetics and interphase fluorescence in situ 
      hybridization analysis in newly diagnosed multiple myeloma in Taiwan.
PG  - 1530-8
AB  - BACKGROUND: The incidence of multiple myeloma (MM) is lower in Asia than in 
      Western countries. However, it is not known whether cytogenetic abnormalities 
      (CA) characteristic of MM in Asia differ from those documented in the West. 
      PATIENTS AND METHODS: We analyzed CA by conventional cytogenetics (CG) and/or 
      fluorescence in situ hybridization (FISH), assessed their clinical significance 
      in 150 Chinese MM patients and compared our data with that derived from Western 
      countries. RESULTS: CA were detected by CG (CG_CA) in 44 (29.3%) of the 150 
      patients and by FISH (FISH_CA) in 59 (67%) of the 88 patients studied. Presence 
      of either CG_CA or FISH_CA was associated with a poor prognosis. Patients with 
      CG_CA and hyperdiploid chromosomes, always associated with several trisomies, had 
      a longer survival (median 25 months versus 12 months; P=0.025) in comparison with 
      those with non-hyperdiploid chromosomes, usually associated with a monosomy 
      13/partial deletion of 13q (Delta13) and a rearrangement of 14q32. A novel 
      recurrent CG_CA, add(19)(p13), was found in four patients: all males with 
      immunoglobulin G/lambda isotypes, extramedullary myeloma at diagnosis and a poor 
      prognosis. Three groups of patients with significantly different survival, 
      CG_Delta13, FISH_Delta13 but without CG_Delta13, and neither CG_Delta13 nor 
      FISH_Delta13 (median 9 versus 15 versus 32 months; P=0.013) were identified. 
      CONCLUSIONS: We conclude that MM CA in our patients are similar to those noted in 
      Western countries, and that combined CG and FISH analysis can predict prognosis. 
      The clinical significance of add(19)(p13) needs to be further investigated.
FAU - Huang, S-Y
AU  - Huang SY
AD  - Department of Internal Medicine, National Taiwan University Hospital, Taipei, 
      Taiwan.
FAU - Yao, M
AU  - Yao M
FAU - Tang, J-L
AU  - Tang JL
FAU - Tsay, W
AU  - Tsay W
FAU - Lee, F-Y
AU  - Lee FY
FAU - Liu, M-C
AU  - Liu MC
FAU - Wang, C-H
AU  - Wang CH
FAU - Chen, Y-C
AU  - Chen YC
FAU - Shen, M-C
AU  - Shen MC
FAU - Tien, H-F
AU  - Tien HF
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20050606
PL  - England
TA  - Ann Oncol
JT  - Annals of oncology : official journal of the European Society for Medical 
      Oncology
JID - 9007735
SB  - IM
MH  - Aged
MH  - *Cytogenetics
MH  - Female
MH  - Humans
MH  - In Situ Hybridization, Fluorescence
MH  - *Interphase
MH  - Male
MH  - Middle Aged
MH  - Multiple Myeloma/drug therapy/*genetics/pathology
MH  - Sensitivity and Specificity
MH  - Taiwan
EDAT- 2005/06/09 09:00
MHDA- 2006/01/28 09:00
CRDT- 2005/06/09 09:00
PHST- 2005/06/09 09:00 [pubmed]
PHST- 2006/01/28 09:00 [medline]
PHST- 2005/06/09 09:00 [entrez]
AID - S0923-7534(19)54980-8 [pii]
AID - 10.1093/annonc/mdi273 [doi]
PST - ppublish
SO  - Ann Oncol. 2005 Sep;16(9):1530-8. doi: 10.1093/annonc/mdi273. Epub 2005 Jun 6.